Proactiveinvestors recommends
Additional Information
Market: NYSE AMEX
Sector: Medical
EPIC: ISR
IsoRay
www.isoray.com

IsoRay was founded in Richland, Washington in 1998 to develop, manufacture and market isotopes for use in the medical treatment of various malignant diseases

Full IsoRay profile here
Pdf

IsoRay’s Announces First Implantation Of Its Cancer Treatment Cesium-131

7th Oct 2010, 7:23 pm
IsoRay’s Announces First Implantation Of Its Cancer Treatment Cesium-131

IsoRay (AMEX: ISR), announced today that the first implantation for its cancer treatment product has been performed.

The company’s Cesium-131, a radioactive capsule that kills cancer cells, was implanted in a patient with lung cancer. Once inside the patient’s body, the capsule will release radioactive elements that will kill the surrounding cancer cells, while having no effect on healthy cells.  Brachytherapy, as the treatment process is called, was used as an alternative because the patient did not have the lung capacity to undergo surgery.

According to IsoRay, over 222,500 Americans develop primary lung cancer each year and more than 100,000 cases of metastasized lung cancers (when the cancer has already spread to other sites) are diagnosed annually.

While originally developed to treat primary cancers, Cesium-131 is now also being used to treat metastasized cancers. Aside from lung cancer, the capsule is now being used to treat prostate, colon, ocular, head and neck cancers as well.

The company estimates that of the 218,890 men who will be diagnosed with prostate cancer in 2010, about 20% will use brachytherapy.

Compared to other brachytherapy capsules, the Cesium-131 has reduced side effects and has a shorter decay time (9.7 days), the company said.

The capsule, which has already received FDA approval, has received wide interest from the medical community, said CEO of IsoRay Dwight Babcok.

The company’s share price rallied 4.3% to trade at $1.20 as of 1:50 pm ET.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.